Lifeward Ltd. Reports Q1 2025: Revenue Drops $0.3M to $5M, Net Loss Narrows to $4.8M, EPS Improves to $0.46

Reuters
05-15
<a href="https://laohu8.com/S/LFWD">Lifeward Ltd</a>. Reports Q1 2025: Revenue Drops $0.<a href="https://laohu8.com/S/MMM">3M</a> to $5M, Net Loss Narrows to $4.8M, EPS Improves to $0.46

Lifeward Ltd., a global leader in medical technology, reported financial results for the first quarter of 2025. The company experienced a net loss of $4.8 million, or $0.46 per share, compared to a net loss of $6.3 million, or $0.73 per share, in the same period of 2024. On a non-GAAP basis, adjusted net loss was $4.6 million, or $0.44 per share, down from $5.3 million, or $0.62 per share, in the first quarter of 2024. Operating loss for the first quarter of 2025 was $4.9 million, compared to $6.5 million in the previous year. Adjusted operating loss, excluding certain items, was $4.6 million, an improvement from the $5.5 million loss in the first quarter of 2024. Operating expenses decreased to $7.0 million in the first quarter of 2025 from $7.9 million in the same period of 2024, with adjusted operating expenses at $6.8 million, down from $7.3 million. This decline in expenses was mainly due to savings from the closure of the Fremont location, resource rationalization, and lower development costs following the completion of the ReWalk 7 and AlterG NEO programs. Lifeward reported liquidity of $5.7 million in unrestricted cash and cash equivalents as of March 31, 2025, with no debt. The company anticipates a sequential decline in quarterly cash burn for the remainder of the year. Additionally, Lifeward raised $0.5 million through its ATM facility after the first quarter. For 2025, Lifeward has maintained its revenue guidance, expecting full-year revenues between $28 million and $30 million. The company also highlighted the launch of the ReWalk 7 exoskeleton in the U.S. market following FDA clearance in March. AlterG sites' closure and resource consolidation have led to improved operating expense trends, with AlterG achieving over 15% revenue growth for the second consecutive quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-001811), on May 15, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10